Relafen Related Published Studies
Well-designed clinical trials related to Relafen (Nabumetone)
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. [2009.12]
The effects of aceclofenac and nabumetone in osteoarthritis. [2009.04]
High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. [2008.11]
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. [2006.02]
Pulp-dentine complex changes and root resorption during intrusive orthodontic tooth movement in patients prescribed nabumetone. [2005.01]
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. [2004.11]
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. [2004.05]
Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. [2003.02]
A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. [2002.06]
Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee. [2001.12]
Effect of nabumetone and aspirin on colonic mucosal bleeding time. [2001.04]
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. [2001.04]
Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. [2001.01]
A double-blind study of the effect on hemostasis of nabumetone (Relafen) compared to placebo. [2000.05]
Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. [2000.04]
Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. [2000.01]
Non-steroidal anti-inflammatory drugs and renal response to exercise: a comparison of indomethacin and nabumetone. [1999.10]
Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. [1999.04]
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. [1999.04]
A placebo-controlled study of interaction between nabumetone and acenocoumarol. [1999.04]
Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee. [1999.01]
Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard. [1999]
Effect of nabumetone on hemostasis during arthroscopic knee surgery. [1998.01]
A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group. [1997.07]
[Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee] [1997.06.21]
Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. [1997.06]
The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. [1996.01]
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. [1995.09]
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. [1995.09]
Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. [1995.07]
Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. [1995.07]
A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. [1995.05]
Effects of naproxen and nabumetone on serum cholesterol levels in patients with osteoarthritis. [1995.03]
Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. [1994.11]
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. [1994.06]
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. [1993.11.22]
Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. [1993.08.09]
Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. [1993.08.09]
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. [1993.08.09]
Randomized double-blind study of nabumetone and piroxicam in the treatment of osteoarthritis in Dutch general practice: efficacy and tolerability. [1993.06.18]
Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. [1992.11]
Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: a multicenter, double blind, randomized, parallel group trial in hospital outpatients. [1992.11]
A comparative study of nabumetone and indomethacin in ankylosing spondylitis. [1991]
A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. [1990]
Comparative gastrointestinal blood loss associated with placebo, aspirin, and nabumetone as assessed by radiochromium (51Cr). [1989.03]
Bioequivalence study of nabumetone: tablet versus suspension. [1987.10.30]
Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial. [1987.10.30]
Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis. [1987.10.30]
Single-blind comparative study of nabumetone (Relafen) versus naproxen in the treatment of rheumatoid arthritis. [1987.10.30]
Evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. [1987.10.30]
Nabumetone: a single-center three-week comparison with placebo in the treatment of rheumatoid arthritis. [1987.10.30]
Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation. [1987.10.30]
Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. [1987.10.30]
Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin. [1987.10.30]
A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. [1987]
Well-designed clinical trials possibly related to Relafen (Nabumetone)
WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. [2007.07.18]
Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. [2002.04]
Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. [2001.08.24]
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. [2001.04]
Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. [1999.09]
Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. [1997.02]
Health-related quality of life assessments in osteoarthritis during NSAID treatment. [1996.08]
[Peripheral arthritis in family practice] [1996.04]
Gastrointestinal blood loss after non-steroidal anti-inflammatory drugs. Measurement by selective determination of faecal porphyrins. [1992.01]
[Beta-cyclodextrin-piroxicam in the treatment of the active phase of osteoarthritic pathology] [1990.08]
Other research related to Relafen (Nabumetone)
Single dose oral sulindac for acute postoperative pain in adults. [2009.10.07]
Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. [2009.01]
Safety of the Nonselective NSAID Nabumetone : Focus on Gastrointestinal Tolerability. [2008]
Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. [2007.04]
Severe immediate reaction to nabumetone. [2007]
Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. [2006.11]
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. [2005.11]
Low direct cytotoxicity of nabumetone on gastric mucosal cells. [2005.09]
Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines. [2005.05]
Adverse effect of drug-induced emotional problems on work and daily activities. A principal component as an independent predictor of ADRs in Shanghai patients with osteo-arthropathy taking nabumetone. [2004.06]
A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. [2004.05]
Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. [2004]
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. [2004]
Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity. [2003.07]
Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies. [2003.06.01]
An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. [2003.04]
Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions. [2003.02]
The different patterns of blood pressure elevation by rofecoxib and nabumetone. [2002.06]
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). [2002.01.15]
The effects of nabumetone, a cyclooxygenase-2 inhibitor, on cisplatin-induced 5-hydroxytryptamine release from the isolated rat ileum. [2001.07]
Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. [2001.05.15]
Inclusion complexes of nabumetone with beta-cyclodextrins: thermodynamics and molecular modelling studies. Influence of sodium perchlorate. [2001.03]
Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography. [2000.04.14]
Effect of nabumetone treatment on vascular responses of the thoracic aorta in rat experimental arthritis. [2000.04]
Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. [2000.02]
Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis. [2000.01]
[Rationale for using nabumetone and clinical experience] [2000]
[Properties and features of nabumetone] [2000]
Gastrointestinal safety profile of nabumetone: a meta-analysis. [1999.12.13]
Comparison of acetaminophen, ibuprofen, and nabumetone therapy in rats with pulpal pathosis. [1999.12]
Two cases of nabumetone induced pseudoporphyria. [1999.12]
Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. [1999.03]
Pseudoporphyria induced by nabumetone. [1999.03]
Pseudoporphyria associated with Relafen therapy. [1999.01]
Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. [1998.11]
Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment. [1998.06]
|
